Compare Amphastar Pharmaceuticals Inc (AMPH) vs Danaos Corporation (DAC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

DAC trades at $128.39, up 0.83% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 4.53, P/B of 0.6, and net income margin of 49.85%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company maintains a $0.90 quarterly dividend. Cash flow from operations remains robust at $645 million for 2025.

Outlook is positive given deep value metrics and high profitability, but risks include cyclical shipping demand and earnings volatility. Analyst consensus is mixed with 40% buy ratings. The stock offers value but requires monitoring of charter rate trends and global trade conditions.